natgillin/translations-raw huggingface dataset:
Eluxadoline is a locally acting, mixed mu opioid receptor (μOR) agonist and delta opioid receptor 
Eluksadolin je lokalno delujoč, mešan agonist opioidnih receptorjev mi (μOR) in antagonist opioidnih receptorjev delta (δOR).
In vitro studies indicate that eluxadoline is neither an inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4, nor an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2C8 and CYP2D6 at clinically relevant concentrations. 
CYP1A2, CYP2B6, CYP2C9, CYP2C19 in CYP3A4 niti zaviralec CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2C8 in CYP2D6.
4 “Gastrooesophageal reflux disease” term includes gastrooesophageal reflux disease, dyspepsia and gastritis. 
4 Izraz »gastroezofagealna refluksna bolezen« vključuje gastroezofagealno refluksno bolezen,
However, given the potential for increased sensitivity to experience undesirable effects, it may be considered to initiate eluxadoline treatment in a dosage of 150 mg daily (one 75 mg tablet twice daily). 
Vendar se, glede na možnost povečane občutljivosti za pojav neželenih učinkov, lahko razmisli o začetku zdravljenja z eluksadolinom v odmerku 150 mg dnevno (ena 75 mg tableta dvakrat dnevno).
The occurrence of such events in patients with an intact biliary tract cannot be excluded. 
Pojava takih učinkov pri bolnikih z normalnim žolčevodom ni mogoče izključiti.
However, patients 65 years of age and older, treated with the 75 mg dose twice daily experienced a reduced rate of serious adverse events as well as adverse events leading to discontinuation compared to patients treated with 100 mg dose twice daily (see section 4.8). 
Vendar so bolniki, stari 65 let in več, ki so se zdravili z odmerkom 75 mg dvakrat dnevno, imeli manj resnih neželenih učinkov in neželenih učinkov, ki so pripeljali do prekinitve zdravljenja, v primerjavi z bolniki, zdravljenimi s 100 mg dvakrat dnevno (glejte poglavje 4.8).
If you have taken more Truberzi than you should, tell your doctor or seek urgent medical assistance. 
Če ste vzeli večji odmerek zdravila Truberzi, kot bi smeli Če ste vzeli večji odmerek zdravila Truberzi, kot bi smeli, obvestite svojega zdravnika ali poiščite nujno zdravniško pomoč.
IBS is a common gut disorder. 
IBS je pogosta črevesna bolezen.
Patients should be instructed to stop the medicinal product and seek medical attention if they develop severe constipation (see section 4.4). 
Bolnikom je treba naročiti, naj prenehajo jemati zdravilo in poiščejo zdravniško pomoč, če se pojavi huda zaprtost (glejte poglavje 4.4).
Eluxadoline has a low potential for drug-drug interactions based on limited in vitro CYP inhibition/induction and given that eluxadoline is not a substrate for CYPs at clinically meaningful concentrations. 
Eluksadolin ima majhen potencial za interakcije z drugimi zdravili glede na omejeno inhibicijo/indukcijo CYP in vitro in glede na to, da ni substrat encimov CYP pri klinično pomembnih koncentracijah.
Eluxadoline has demonstrated efficacy in normalizing GI transit and defecation in several models of stress induced or post GI inflammation-altered GI function in animals. 
Eluksadolin je pokazal učinkovitost pri normalizaciji prehoda skozi prebavila in odvajanja blata na več živalskih modelih spremenjenega delovanja prebavil, povzročenega s stresom ali kot posledice vnetja prebavil.
• Patients on treatment with potent inhibitors of OATP1B1 (e.g. cyclosporine) 
• Bolniki, ki se zdravijo z močnimi zaviralci OATP1B1 (npr. ciklosporinom).
Truberzi acts on the surface of your gut to restore the normal function of your bowels and block the sensation of pain and discomfort in IBS-D patients. 
Zdravilo Truberzi deluje na površini črevesa za obnovitev njegovega normalnega delovanja ter zavira bolečino in neprijeten občutek pri bolnikih s sindromom IBS-D.
In vitro studies in human liver microsomes showed that eluxadoline is not a direct inhibitor of CYP3A4 at clinically relevant concentrations [IC50 =450 µM] but in human intestinal microsomes, eluxadoline was a metabolism dependent inhibitor of CYP3A4 with kinact of 0.1 min-1 and K-I of 450 µM (256 µg/mL). 
Študije in vitro na človeških jetrnih mikrosomih so pokazale, da eluksadolin ni neposreden zaviralec CYP3A4 pri klinično pomembnih koncentracijah [IC50 = 450 µM], pri človeških jetrnih mikrosomih pa je od presnove odvisen zaviralec CYP3A4 s kinact = 0,1 min-1 in K-I = 450 µM (256 µg/ml).
CYP2E1 was slightly inhibited (50% 
Rahlo je zavrl CYP2E1 (50 % zaviralne koncentracije
Film-coated tablets 28 tablets 
filmsko obložene tablete 28 tablet
All events of sphincter of Oddi spasm occurred in patients without a gallbladder. 
Vsi učinki spazma Oddijevega sfinktra so se pojavili pri bolnikih brez žolčnika.
It is used to treat irritable bowel syndrome (‘IBS') with diarrhoea (IBS-D) in adults. 
Uporablja se za zdravljenje sindroma razdražljivega črevesa (»IBS«) z drisko (»IBS-D«) pri odraslih.
For the daily composite response, eluxadoline began to separate from placebo shortly after initiating treatment with a maximal effect seen at 4-6 weeks that was maintained throughout the course of treatment. 
Pri dnevnem sestavljenem odzivu se je eluksadolin začel razlikovati od placeba kmalu po začetku zdravljenja; učinek je bil največji po 4-6 tednih in se je ohranil v celotnem obdobju zdravljenja.
If any of the above applies to you, tell your doctor or pharmacist before taking Truberzi. 
Če kaj od naštetega velja za vas, pred jemanjem zdravila Truberzi obvestite svojega zdravnika ali farmacevta.
Patients with known or suspected sphincter of Oddi disease or dysfunction and/or biliary tract or pancreatic disease, including a history of pancreatitis, must not receive Truberzi (see section 4.3). 
Bolniki z znano ali domnevno boleznijo ali nepravilnim delovanjem Oddijevega sfinktra in/ali boleznijo žolčnih poti ali trebušne slinavke, vključno z anamnezo pankreatitisa, ne smejo prejeti zdravila Truberzi (glejte poglavje 4.3).
Efficacy of eluxadoline was assessed using an overall responder analyses as defined by the simultaneous improvement in the daily WAP score by ≥30% as compared to the baseline weekly average AND a reduction in the BSS to <5 on at least 50% of the days within a time interval. 
Učinkovitost eluksadolina je bila ocenjena z analizo splošnega odziva, opredeljenega s sočasnim izboljšanjem dnevne ocene WAP za ≥ 30 % v primerjavi z izhodiščnim tedenskim povprečjem IN z zmanjšanjem ocene BSS na <5 na najmanj 50 % dni v določenem časovnem intervalu.
However, you may experience side effects such as sleepiness or dizziness while taking Truberzi which might affect your ability to drive or use machines. 
Vendar se lahko med jemanjem zdravila Truberzi pojavijo neželeni učinki, kot sta zaspanost in omotica, ki lahko vplivajo na vašo sposobnost vožnje ali upravljanja s stroji.
Systemic exposure to medicinal products metabolised by CYP3A4 may be decreased when coadministered with Eluxadoline. 
Sistemska izpostavljenost zdravilom, ki se presnavljajo s CYP3A4, se lahko ob sočasni uporabi z eluksadolinom zmanjša.
There is limited amount of data from the use of eluxadoline in pregnant women. 
Podatki o uporabi eluksadolina pri nosečnicah so omejeni.
If you forget to take Truberzi 
Če ste pozabili vzeti zdravilo Truberzi
Eluxadoline increases the exposure of the co-administered OATP1B1 substrate; rosuvastatin (see section 5.2) by up to 40% of the total exposure which is usually not considered to be clinically relevant. 
Substrati OATP1B1 Eluksadolin poveča izpostavljenost sočasno uporabljenemu substratu OATP1B1, rosuvastatinu (glejte poglavje 5.2), za do 40 % celotne izpostavljenosti, kar navadno ne šteje za klinično pomembno.
These symptoms occur uncommonly (may affect up to 1 in 100 people) and may indicate pancreas or bile duct system problems (e.g. inflammation of the pancreas or spasm of the sphincter of Oddi). 
Ti simptomi so občasni (pojavijo se lahko pri največ 1 od 100 ljudi) in lahko kažejo na težave s trebušno slinavko ali žolčevodom (npr. vnetje trebušne slinavke ali spazem Oddijevega sfinktra).
Avoid taking Truberzi with any other medicines that may cause constipation such as opioids (e.g. fentanyl [used to treat pain]) or anticholinergics (e.g. atropine [used to treat cardiac disorders among other indications]). 
Izogibajte se jemanju zdravila Truberzi s katerimkoli drugim zdravilom, ki bi lahko povzročilo zaprtost, kot so opioidi (npr. fentanil [za lajšanje bolečine]) ali antiholinergiki (npr. atropin [ki se poleg drugih indikacij uporabljajo za zdravljenje bolezni srca]).
In clinical studies, events of sphincter of Oddi spasm manifested as elevated hepatic enzymes associated with abdominal pain in 8 patients, pancreatitis in 1 patient and abdominal pain with lipase elevation less than 3 times the upper limit of normal in 1 patient. 
V kliničnih študijah se je spazem Oddijevega sfinktra izrazil kot zvišana raven jetrnih encimov s spremljajočimi bolečinami v trebuhu pri 8 bolnikih, kot pankreatitis pri 1 bolniku in kot bolečine v trebuhu z zvišano ravnjo lipaze do manj kot 3-kratne zgornje meje normalne vrednosti pri 1 bolniku.
Truberzi is contraindicated in patients without a gallbladder and other conditions that increase the risk of developing pancreatitis (see section 4.3). 
Zdravilo Truberzi je kontraindicirano pri bolnikih brez žolčnika in pri drugih stanjih, ki povečujejo tveganje za pojav pankreatitisa (glejte poglavje 4.3).
Eluxadoline is also an agonist at the kappa opioid receptor (κOR). 
Eluksadolin je tudi agonist opioidnih receptorjev kapa (κOR).
Avoid use with other drugs that may cause constipation (see section 4.5). 
Izogibajte se istočasni uporabi z zdravili, ki lahko povzročijo zaprtost (glejte poglavje 4.5).
For patients who are unable to tolerate the 200 mg daily dose (one 100 mg tablet, twice daily), the dose can be lowered to 150 mg daily (one 75 mg tablet twice daily). 
Pri bolnikih, ki ne morejo prenašati dnevnega odmerka 200 mg (po ena 100 mg tableta dvakrat dnevno), se lahko odmerek zmanjša na 150 mg dnevno (po ena 75 mg tableta dvakrat dnevno).
If you stop taking Truberzi 
Če ste prenehali jemati zdravilo Truberzi
Eluxadoline must not be used in patients with a history of or known or suspected hepatic impairment (Child-Pugh Class A-C) (see section 4.3). 
Eluksadolin se ne sme uporabljati pri bolnikih z anamnezo okvare jeter ali znano ali domnevno okvaro jeter (Child-Pugh razred A-C) (glejte poglavje 4.3).
Unchanged eluxadoline recovered in urine was 0.01% and 0.05% of dose in ESRD and healthy participants, respectively. 
Nespremenjeni eluksadolin, izločen v urinu, je znašal 0,01 % pri udeležencih s končno fazo ledvične odpovedi (ESRD) in 0,05 % pri zdravih udeležencih.
• an average daily stool consistency score (BSS) of ≥5.5 and at least 5 days with a BSS score ≥5 
• povprečna dnevna ocena konsistence blata (BSS) ≥5,5 in vsaj 5 dni z oceno BSS ≥5 na lestvici od 1 do 7 v tednu pred randomizacijo.
Truberzi is indicated in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D). 
Zdravilo Truberzi je indicirano pri odraslih za zdravljenje sindroma razdražljivega črevesa z drisko (IBS-D - irritable bowel syndrome with diarrhoea).
In both studies, the proportion of patients who were composite responders to Truberzi 100 mg twice daily was statistically significantly higher than placebo. 
V obeh študijah je bil delež bolnikov s sestavljenim odzivom na zdravilo Truberzi v odmerku 100 mg dvakrat dnevno statistično pomembno večji kot pri placebu.
In animals, eluxadoline interacts with opioid receptors in the gut. 
Pri živalih eluksadolin sodeluje z opioidnimi receptorji v črevesju.
Since bioavailability is limited, the pharmacodynamic activity of eluxadoline is based predominantly on local action within the GI tract. 
Glede na omejeno biološko uporabnost temelji farmakodinamična aktivnost eluksadolina zlasti na lokalnem delovanju v prebavilih.
Patients should be instructed to stop the treatment immediately and seek medical attention if they experience symptoms suggestive of sphincter of Oddi spasm such as acute worsening of abdominal pain (e.g. acute epigastric or biliary [i.e., right upper quadrant] pain) that may radiate to the back or shoulder, with or without nausea and vomiting. 
Bolnikom je treba naročiti, naj nemudoma prenehajo jemati zdravilo in poiščejo zdravniško pomoč, če se pojavijo simptomi, ki nakazujejo spazem Oddijevega sfinktra, kot je akutno poslabšanje bolečine v trebuhu (npr. akutna epigastrična ali biliarna bolečina [tj. v zgornjem desnem kvadrantu]), ki lahko seva v hrbet ali rame, z navzeo in bruhanjem ali brez njiju.
Upon administration of multiple oral doses twice daily, there was no accumulation of active substance. 
Po uporabi več peroralnih odmerkov dvakrat dnevno ni prišlo do kopičenja učinkovine.
Eluxadoline should not be administered concomitantly with such medicinal products (see section 4.3). 
Eluksadolin se ne sme uporabljati sočasno s takimi zdravili (glejte poglavje 4.3).
Increased ALT Increased AST 1“Somnolence” term includes: somnolence and sedation. 
1 Izraz »zaspanost« vključuje: zaspanost in sedacijo.
Placebo n=382 
Placeb o n=382
• A history of pancreatitis; or known or suspected structural diseases of the pancreas, including pancreatic duct obstruction. 
• Anamneza pankreatitisa ali znane ali domnevne strukturne bolezni trebušne slinavke, vključno z zaporo vodov trebušne slinavke.
However, in a clinical study in healthy subjects, administration of eluxadoline 100 mg twice daily for one week, with a single oral dose of 4 mg of midazolam resulted in no change to the midazolam Cmax and a slight decrease in AUC (~10%). 
Vendar pa v klinični študiji, izvedeni pri zdravih osebah, uporaba 100 mg eluksadolina en teden dvakrat dnevno, z enim peroralnim odmerkom 4 mg midazolama, ni povzročila spremembe Cmax midazolama,
Eluxadoline also reverses hyperalgesic responses in an animal model of acute colitis-induced visceral pain. 
Eluksadolin tudi odpravi hiperalgezične odzive pri živalskem modelu akutne visceralne bolečine, ki je posledica kolitisa.
Risk of constipation with eluxadoline in patients with other IBS sub-types is unknown, but may be increased. 
Tveganje za pojav zaprtosti med zdravljenjem z eluksadolinom pri bolnikih z drugimi podtipi sindroma razdražljivega črevesa ni znano, vendar je lahko zvečano.
Single supratherapeutic oral doses of eluxadoline up to 1,000 mg and single intranasal doses up to 200 mg were associated with a higher incidence of adverse events than a 100 mg single dose, especially gastrointestinal and central nervous system events. 
Posamezni supraterapevtski peroralni odmerki eluksadolina do 1000 mg in posamezni intranazalni odmerki do 200 mg so bili v primerjavi s posameznim odmerkom 100 mg povezani z večjo incidenco neželenih učinkov, zlasti na prebavila in osrednje živčevje.
Eluxadoline has a minor influence on the ability to drive and use machines. 
Eluksadolin ima blag vpliv na sposobnost vožnje in upravljanja strojev.
The frequency of serious adverse events, gastrointestinal events, and events leading to discontinuation tended to be lower for the 75 mg dose compared to the 100 mg dose. 
Pogostnost resnih neželenih učinkov, učinkov na prebavila in učinkov, ki so povzročili prenehanje zdravljenja, je bila večinoma manjša pri odmerku 75 mg v primerjavi s 100 mg.
What Truberzi looks like and contents of the pack 
Izgled zdravila Truberzi in vsebina pakiranja
Stop taking Truberzi right away and get emergency medical care if you have signs or symptoms of an allergic reaction, including: - swelling of your face, lips, mouth, tongue, and/or throat - shortness of breath or other breathing problems - chest pain or tightness - itching - rash - hives 
Takoj prenehajte jemati zdravilo Truberzi in poiščite zdravniško pomoč, če imate znake ali simptome alergijske reakcije, kar vključuje: - oteklino obraza, ustnic, ust, jezika in/ali žrela; - težko dihanje ali druge težave z dihanjem;
Patients receiving eluxadoline also reported significant reductions in bowel movement frequency and abdominal bloating compared to placebo as demonstrated by changes from baseline in daily bowel movements and bloating score at Weeks 12 and 26. 
Bolniki, ki so prejemali eluksadolin, so poročali tudi o pomembnem zmanjšanju pogostosti odvajanja blata in napihnjenosti trebuha v primerjavi s placebom, kot je razvidno iz sprememb v primerjavi z izhodiščem v dnevnem odvajanju blata in oceni napihnjenosti v 12. in 26. tednu.
Truberzi is available in packs containing 28 or 56 film-coated tablets and in a multipack of 168 film-coated tablets comprising 3 cartons, each containing 56 film-coated tablets. 
Zdravilo Truberzi je na voljo v pakiranjih, ki vsebujejo po 28 ali 56 filmsko obloženih tablet, in v velikih pakiranjih s 168 filmsko obloženimi tabletami, ki vsebujejo 3 škatle po 56 filmsko obloženih tablet.
In patients with IBS-D, no signal for central nervous system-mediated adverse events was identified. 
Pri bolnikih z IBS-D niso ugotovili nobenih znakov neželenih učinkov, ki bi nastali zaradi vpliva na osrednje živčevje.
Patients should be informed of and monitored for signs and symptoms suggestive of pancreatitis e.g. abdominal pain, that may radiate to the back or shoulder, nausea and vomiting. 
Bolnike je treba o tem poučiti in pri njih spremljati pojav znakov in simptomov, ki kažejo na pankreatitis, npr. bolečine v trebuhu, ki se lahko širijo v hrbet ali ramena, navzea in bruhanje.
Given eluxadoline's action at opioid receptors, administration of a narcotic mu opioid antagonist, such as naloxone, should be considered. 
Glede na delovanje eluksadolina na opioidne receptorje je treba razmisliti o uporabi opioidnega antagonista receptorjev mi z narkotičnim učinkom, kot je nalokson.
The most common adverse reactions (incidence of >5%) reported were constipation (7% and 8% of patients receiving 75 mg and 100 mg respectively), nausea (8% and 7% of patients receiving 75 mg and 100 mg respectively) and abdominal pain (6% and 7% of patients receiving 75 mg and 100 mg respectively). 
Najpogostejši opaženi neželeni učinki (incidenca >5 %) so bili zaprtost (pri 7 % bolnikov, ki so prejemali 75 mg, in pri 8 % bolnikov, ki so prejemali 100 mg), navzea (pri 8 % bolnikov, ki so prejemali 75 mg, in pri 7 % bolnikov, ki so prejemali 100 mg) in bolečine v trebuhu (pri 6 % bolnikov, ki so prejemali 75 mg, in pri 7 % bolnikov, ki so prejemali 100 mg).
Stop taking Truberzi and call your doctor right away if you develop severe constipation while taking Truberzi. 
Takoj prenehajte jemati zdravilo Truberzi in se posvetujte s svojim zdravnikom, če imate med jemanjem zdravila Truberzi hudo zaprtje.
These medicines can include: - rosuvastatin (statin used to treat high cholesterol and to prevent cardiovascular disease); - valsartan and olmesartan (used to treat high blood pressure); 
- rosuvastatin (statin, ki se uporablja za zdravljenje visoke ravni holesterola ter za preprečevanje bolezni srca in ožilja); - valsartan in olmesartan (uporabljata se za zdravljenje visokega krvnega tlaka);
Truberzi is a medicine that contains the active substance eluxadoline. 
Truberzi je zdravilo, ki vsebuje zdravilno učinkovino eluksadolin.
• A history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction. 
• Anamneza kronične ali hude zaprtosti ali posledic zaprtosti ali znana ali domnevna mehanska zapora prebavil.
The main symptoms of IBS-D include: - stomach ache; - stomach discomfort; - diarrhoea; - urgent bowel movements. 
Glavni simptomi IBS-D vključujejo: - bolečine v trebuhu; - neprijeten občutek v trebuhu;
Eluxadoline's systemic exposure following oral administration is low and is consistent with its local action in the GI tract. 
Sistemska izpostavljenost eluksadolinu po peroralni uporabi je majhna in skladna z njegovim lokalnim delovanjem v prebavilih.
Stop taking Truberzi and seek medical attention immediately if you develop any of the following while taking this medicine: - new or worsening pain in the belly, with or without nausea and vomiting; 
Prenehajte jemati zdravilo Truberzi in takoj poiščite zdravniško pomoč, če se pri vas med jemanjem tega zdravila pojavi kar koli od naslednjega: - nova ali poslabšana bolečina v trebuhu, s siljenjem na bruhanje in bruhanjem ali brez njiju;
Eluxadoline has very low oral bioavailability and exerts no detectable central nervous system (CNS)-mediated effects when administered orally to animals at effective doses. 
Eluksadolin ima zelo majhno peroralno biološko uporabnost in nima zaznavnih učinkov na osrednje živčevje, če se peroralno daje živalim v učinkovitih odmerkih.
Overall, there was an increased frequency of adverse events reported for patients aged 65 years or greater in the clinical studies. 
V splošnem so v kliničnih študijah poročali o zvečani pogostnosti neželenih učinkov pri bolnikih, starih 65 let ali več.
Hepatic impairment or coadministration with cysclosporine results in significant increases in plasma concentrations of eluxadoline. 
Okvara jeter ali sočasna uporaba s ciklosporinom povzroči pomembno zvišanje plazemskih koncentracij eluksadolina.
An abuse liability study with 100 mg and 200 mg intranasal doses of eluxadoline resulted in higher systemic concentrations of eluxadoline that produced changes in pupil diameter but were associated with drug disliking. 
V študiji tveganja za zlorabo z intranazalnimi odmerki eluksadolina 100 mg in 200 mg so bile sistemske koncentracije eluksadolina višje in so povzročile spremembe premera zenice, vendar so bile povezane z neugodjem pri uporabi zdravila.
Additional cases of pancreatitis not associated with sphincter of Oddi spasm were reported in clinical studies. 
V kliničnih študijah so poročali o dodatnih primerih pankreatitisa, ki niso bili povezani s spazmom Oddijevega sfinktra.
Serious adverse reactions of pancreatitis (0.2% and 0.3% of patients receiving 75 mg and 100 mg respectively) and sphincter of Oddi spasm (0.2% of patients receiving 75 mg and 0.8% of patients receiving 100 mg) may also occur. 
Lahko se pojavita tudi resna neželena učinka pankreatitis (pri 0,2 % bolnikov, ki so prejemali 75 mg, in pri 0,3 % bolnikov, ki so prejemali 100 mg) in spazem Oddijevega sfinktra (pri 0,2 % bolnikov, ki so prejemali 75 mg, in pri 0,8 % bolnikov, ki so prejemali 100 mg).
Due to events of somnolence and sedation observed in clinical studies, caution should be exercised (see sections 4.4 and 4.5). 
V kliničnih študijah so opazili pojav zaspanosti in sedacije, zato je potrebna previdnost (glejte poglavji 4.4 in 4.5).
Co-administration of eluxadoline with rosuvastatin (an OATP1B1 substrate) resulted in an up to 1.4-fold increase in exposure of rosuvastatin and the major active metabolite, n-desmethyl rosuvastatin compared to administration of rosuvastatin alone. 
Pri sočasni uporabi eluksadolina z rosuvastatinom (substrat OATP1B1) je prišlo do 1,4-kratnega povečanja izpostavljenosti rosuvastatinu in glavnemu aktivnemu presnovku, N-desmetil rosuvastatinu, v primerjavi z uporabo samega rosuvastatina.
The proportion of patients who were global symptom responders was statistically significantly higher than placebo for Truberzi 100 mg twice daily over 6 month interval in Study 2 and numerically higher than placebo in Study 1. 
Delež bolnikov z odzivom globalnih simptomov je bil statistično pomembno večji od placeba za zdravilo Truberzi v odmerku 100 mg dvakrat dnevno v 6-mesečnem obdobju v študiji 2 in številčno večji od placeba v študiji 1.
These medicines can include: - ciclosporin (immunosuppressant used to reduce inflammation); - gemfibrozil (used to lower lipid levels); - atazanavir, lopinavir, ritonavir, saquinavir, tipranavir (antiretrovirals used to treat HIV); - rifampicin (antibiotic used to treat infections). 
Med temi zdravili so lahko: - ciklosporin (imunosupresiv, ki se uporablja za zmanjšanje vnetja); - gemfibrozil (uporablja se za zniževanje ravni lipidov); - atazanavir, lopinavir, ritonavir, sakvinavir, tipranavir (protiretrovirusna zdravila za zdravljenje okužbe z virusom HIV); - rifampicin (antibiotik za zdravljenje okužb).